Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma

Journal of Medical Genetics

Volumn 45, Issue 3, 2008, Pages 142-146

  Worrillow, L J ^a   Smith, A G ^a   Scott, K ^a   Andersson, M ^b   Ashcroft, A J ^c   Dores, G M ^d,e   Glimelius, B ^f   Holowaty, E ^g   Jackson, G H ^h   Jones, G L ^h   Lynch, C F ⁱ   Morgan, G ^j   Pukkala, E ^k   Scott, D ^l   Storm, H H ^b   Taylor, P R ^h   Vyberg, M ^m   Willett, E ^a   Travis, L B ^e,n   Allan, J M ^o  

^a UNIVERSITY OF YORK   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g CANCER CARE ONTARIO   (Canada)

^h ROYAL VICTORIA INFIRMARY   (United Kingdom)

ⁱ UNIVERSITY OF IOWA   (United States)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k FINNISH CANCER REGISTRY   (Finland)

^l HARROGATE AND DISTRICT NHS FOUNDATION TRUST   (United Kingdom)

^m AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁿ EXPONENT INC   (United States)

^o NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN DERIVATIVE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PROCARBAZINE; PROTEIN MLH1; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DNA CROSS LINKING; FEMALE; GENE FREQUENCY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA METHYLATION; DNA PRIMERS; DNA REPAIR; FEMALE; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 40649083082     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2007.053850     Document Type: Article

References (23)

1. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, Van't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
2. Schonfeld SJ, Gilbert ES, Dores GM, Lynch CF, Hodgson DC, Hall P, Storm H, Andersen A, Pukkala E, Holowaty E, Kaijser M, Andersson M, Joensuu H, Fossa SD, Allan JM, Travis LB. Acute myeloid leukaemia following Hodgkin lymphoma, a population-based study of 35,511 patients. J Natl Cancer Inst 2006;98:215-18.
3. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V. Secondary myeloid leukaemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3440-6.
4. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
5. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fossa SD, Travis LB. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007;25:1489-97.
6. Loveless A. Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature 1969;223:206-7.
7. Margison GP, Santibanez Koref MF, Povey AC. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002;17:483-7.
8. Iyer BR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev 2006;106:302-23.
9. Griffin S, Branch P, Xu YZ, Karran P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 1994;33:4787-93.
10. York SJ, Modrich P. Mismatch repair-dependent iterative excision at irreparable O6-methylguanine lesions in human nuclear extracts. J Biol Chem 2006;281:22674-83.
11. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roddam PL, Roman E, Cartwright RA, Morgan GJ. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia. Proc Natl Acad Sci U S A 2001;98:11592-7.
12. Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, Jang SS, Kim CH, Lee WK, Kam S, Park RW, Kim IS, Jung TH, Park JY. -93G→A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 2004;112:678-82.
13. Raptis S, Mrkonjic M, Green RC, Pethe W, Monga N, Chan YM, Daftary D, Dicks E, Younghusband BH, Parfrey PS, Gallinger SS, McLaughlin JR, Knight JA, Bapat B. MLH1 -93G→A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst 2007;99:463-74.
14. Beiner ME, Rosen B, Fyles A, Harley I, Pal T, Siminovitch K, Zhang S, Sun P, Narod SA. Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 2006;15:1636-40.
15. Arita M, Zhong X, Min Z, Hemmi H, Shimatake H. Multiple sites reguired for expression in 5′-flanking region of the hMLH1 gene. Gene 2003;306:57-65.
16. Kane EV, Roman E, Cartwright R, Parker J, Morgan G. Tobacco and the risk of acute leukaemia in adults. Br J Cancer 1999;81:1228- 33.
17. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75.
18. Willett EV, O'Connor S, Smith AG, Roman E. Does smoking or alcohol modify the risk of Epstein-Barr virus genome-positive or -negative Hodgkin lymphoma? Epidemiology 2007;18:130-6.
19. Ito E, Yanagisawa Y, Iwahashi Y, Suzuki Y, Nagasaki H, Akiyama Y, Sugano S, Yuasa Y, Maruyama K. A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 1999;256:488-94.
20. Breslow NE, Day NE. Classical methods of analysis of matched data. Statistical methods in cancer research: The analysis of case-control studies volume 1. Lyon: International Agency for Research in Cancer, 1980:162-89.
21. World Health Organisation, International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans, overall evaluation of carcinogenicity: an updating of IARC monographs 1-42. IARC Mongr Eval Carcinog Risks Hum Suppl 1987;(Supplement 7).
22. van Leeuwen FE, Travis LB. Second cancers. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins, 2005:2575-602.
23. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB. Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH. Cancer survivorship - genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.